ID   DYR_ECOLI               Reviewed;         159 AA.
AC   P0ABQ4; P00379;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   15-MAR-2017, entry version 113.
DE   RecName: Full=Dihydrofolate reductase;
DE            EC=1.5.1.3;
GN   Name=folA; Synonyms=tmrA; OrderedLocusNames=b0048, JW0047;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   PROTEIN SEQUENCE (ISOZYME 1).
RC   STRAIN=B [RT500];
RX   PubMed=320005; DOI=10.1111/j.1432-1033.1977.tb11284.x;
RA   Stone D., Phillips A.W., Burchall J.J.;
RT   "The amino-acid sequence of the dihydrofolate reductase of a
RT   trimethoprim-resistant strain of Escherichia coli.";
RL   Eur. J. Biochem. 72:613-624(1977).
RN   [2]
RP   PROTEIN SEQUENCE.
RC   STRAIN=B [MB1428];
RX   PubMed=350268; DOI=10.1021/bi00600a030;
RA   Bennett C.D., Rodkey J.A., Sondey J.M., Hirschmann R.;
RT   "Dihydrofolate reductase: the amino acid sequence of the enzyme from a
RT   methotrexate-resistant mutant of Escherichia coli.";
RL   Biochemistry 17:1328-1337(1978).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=6159575; DOI=10.1093/nar/8.10.2255;
RA   Smith D.R., Calvo J.M.;
RT   "Nucleotide sequence of the E coli gene coding for dihydrofolate
RT   reductase.";
RL   Nucleic Acids Res. 8:2255-2274(1980).
RN   [4]
RP   PROTEIN SEQUENCE (ISOZYME 2).
RC   STRAIN=B [RT500];
RX   PubMed=7007370;
RA   Baccanari D.P., Stone D., Kuyper L.;
RT   "Effect of a single amino acid substitution on Escherichia coli
RT   dihydrofolate reductase catalysis and ligand binding.";
RL   J. Biol. Chem. 256:1738-1747(1981).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=1810;
RX   PubMed=3549289; DOI=10.1111/j.1432-1033.1987.tb10664.x;
RA   Flensburg J., Skoeld O.;
RT   "Massive overproduction of dihydrofolate reductase in bacteria as a
RT   response to the use of trimethoprim.";
RL   Eur. J. Biochem. 162:473-476(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=1630901; DOI=10.1093/nar/20.13.3305;
RA   Yura T., Mori H., Nagai H., Nagata T., Ishihama A., Fujita N.,
RA   Isono K., Mizobuchi K., Nakata A.;
RT   "Systematic sequencing of the Escherichia coli genome: analysis of the
RT   0-2.4 min region.";
RL   Nucleic Acids Res. 20:3305-3308(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [9]
RP   IDENTIFICATION BY 2D-GEL.
RX   PubMed=9298644; DOI=10.1002/elps.1150180805;
RA   VanBogelen R.A., Abshire K.Z., Moldover B., Olson E.R.,
RA   Neidhardt F.C.;
RT   "Escherichia coli proteome analysis using the gene-protein database.";
RL   Electrophoresis 18:1243-1251(1997).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   PubMed=6815179;
RA   Filman D.J., Bolin J.T., Matthews D.A., Kraut J.;
RT   "Crystal structures of Escherichia coli and Lactobacillus casei
RT   dihydrofolate reductase refined at 1.7-A resolution. II. Environment
RT   of bound NADPH and implications for catalysis.";
RL   J. Biol. Chem. 257:13663-13672(1982).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=2185835; DOI=10.1021/bi00465a018;
RA   Bystroff C., Oatley S.J., Kraut J.;
RT   "Crystal structures of Escherichia coli dihydrofolate reductase: the
RT   NADP+ holoenzyme and the folate.NADP+ ternary complex. Substrate
RT   binding and a model for the transition state.";
RL   Biochemistry 29:3263-3277(1990).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=1998681; DOI=10.1021/bi00222a028;
RA   Bystroff C., Kraut J.;
RT   "Crystal structure of unliganded Escherichia coli dihydrofolate
RT   reductase. Ligand-induced conformational changes and cooperativity in
RT   binding.";
RL   Biochemistry 30:2227-2239(1991).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEXES WITH NADPH;
RP   FOLATE; 5-DEAZAFOLATE AND 5,10-DIDEAZATETRAHYDROFOLATE.
RX   PubMed=7873554; DOI=10.1021/bi00008a039;
RA   Reyes V.M., Sawaya M.R., Brown K.A., Kraut J.;
RT   "Isomorphous crystal structures of Escherichia coli dihydrofolate
RT   reductase complexed with folate, 5-deazafolate, and 5,10-
RT   dideazatetrahydrofolate: mechanistic implications.";
RL   Biochemistry 34:2710-2723(1995).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH
RP   5-FORMYLTETRAHYDROFOLATE.
RX   PubMed=8679526; DOI=10.1021/bi960028g;
RA   Lee H., Reyes V.M., Kraut J.;
RT   "Crystal structures of Escherichia coli dihydrofolate reductase
RT   complexed with 5-formyltetrahydrofolate (folinic acid) in two space
RT   groups: evidence for enolization of pteridine O4.";
RL   Biochemistry 35:7012-7020(1996).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEXES WITH NADPH;
RP   METHOTREXATE AND TETRAHYDROFOLATE.
RX   PubMed=9012674; DOI=10.1021/bi962337c;
RA   Sawaya M.R., Kraut J.;
RT   "Loop and subdomain movements in the mechanism of Escherichia coli
RT   dihydrofolate reductase: crystallographic evidence.";
RL   Biochemistry 36:586-603(1997).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH FOLATE,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF MET-16; MET-20; MET-42; CYS-85;
RP   MET-92 AND CYS-152, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16510443; DOI=10.1074/jbc.M508823200;
RA   Iwakura M., Maki K., Takahashi H., Takenawa T., Yokota A.,
RA   Katayanagi K., Kamiyama T., Gekko K.;
RT   "Evolutional design of a hyperactive cysteine- and methionine-free
RT   mutant of Escherichia coli dihydrofolate reductase.";
RL   J. Biol. Chem. 281:13234-13246(2006).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.13 ANGSTROMS).
RX   PubMed=17125251; DOI=10.1021/jm060570v;
RA   Summerfield R.L., Daigle D.M., Mayer S., Mallik D., Hughes D.W.,
RA   Jackson S.G., Sulek M., Organ M.G., Brown E.D., Junop M.S.;
RT   "A 2.13 A structure of E. coli dihydrofolate reductase bound to a
RT   novel competitive inhibitor reveals a new binding surface involving
RT   the M20 loop region.";
RL   J. Med. Chem. 49:6977-6986(2006).
RN   [18]
RP   STRUCTURE BY NEUTRON DIFFRACTION (2.20 ANGSTROMS) IN COMPLEX WITH
RP   METHOTREXATE.
RX   PubMed=17130456; DOI=10.1073/pnas.0604977103;
RA   Bennett B., Langan P., Coates L., Mustyakimov M., Schoenborn B.,
RA   Howell E.E., Dealwis C.;
RT   "Neutron diffraction studies of Escherichia coli dihydrofolate
RT   reductase complexed with methotrexate.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18493-18498(2006).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH METHOTREXATE
RP   AND NADPH.
RX   PubMed=19374017; DOI=10.1016/j.jsb.2009.01.001;
RA   Bennett B.C., Wan Q., Ahmad M.F., Langan P., Dealwis C.G.;
RT   "X-ray structure of the ternary MTX.NADPH complex of the anthrax
RT   dihydrofolate reductase: a pharmacophore for dual-site inhibitor
RT   design.";
RL   J. Struct. Biol. 166:162-171(2009).
CC   -!- FUNCTION: Key enzyme in folate metabolism. Catalyzes an essential
CC       reaction for de novo glycine and purine synthesis, and for DNA
CC       precursor synthesis.
CC   -!- CATALYTIC ACTIVITY: 5,6,7,8-tetrahydrofolate + NADP(+) = 7,8-
CC       dihydrofolate + NADPH. {ECO:0000255|PROSITE-ProRule:PRU00660,
CC       ECO:0000269|PubMed:16510443}.
CC   -!- PATHWAY: Cofactor biosynthesis; tetrahydrofolate biosynthesis;
CC       5,6,7,8-tetrahydrofolate from 7,8-dihydrofolate: step 1/1.
CC   -!- INTERACTION:
CC       P77609:flxA; NbExp=4; IntAct=EBI-550404, EBI-553024;
CC   -!- MISCELLANEOUS: The strain K12 sequence is shown.
CC   -!- MISCELLANEOUS: Strain B [RT500] is resistant to 500 micrograms per
CC       milliliter of trimethoprim.
CC   -!- MISCELLANEOUS: Strain B [MB1428] is methotrexate-resistant.
CC   -!- SIMILARITY: Belongs to the dihydrofolate reductase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J01609; AAA87976.1; -; Genomic_DNA.
DR   EMBL; X05108; CAA28755.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC73159.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAB96616.1; -; Genomic_DNA.
DR   PIR; A93704; RDECD.
DR   RefSeq; NP_414590.1; NC_000913.3.
DR   RefSeq; WP_000624375.1; NZ_LN832404.1.
DR   PDB; 1DDR; X-ray; 2.45 A; A/B=1-159.
DR   PDB; 1DDS; X-ray; 2.20 A; A/B=1-159.
DR   PDB; 1DHI; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 1DHJ; X-ray; 1.80 A; A/B=1-159.
DR   PDB; 1DRA; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 1DRB; X-ray; 1.96 A; A/B=1-159.
DR   PDB; 1DRE; X-ray; 2.60 A; A=1-159.
DR   PDB; 1DRH; X-ray; 2.30 A; A=1-159.
DR   PDB; 1DYH; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 1DYI; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 1DYJ; X-ray; 1.85 A; A/B=1-159.
DR   PDB; 1JOL; X-ray; 1.96 A; A/B=1-159.
DR   PDB; 1JOM; X-ray; 1.90 A; A=1-159.
DR   PDB; 1RA1; X-ray; 1.90 A; A=1-159.
DR   PDB; 1RA2; X-ray; 1.60 A; A=1-159.
DR   PDB; 1RA3; X-ray; 1.80 A; A=1-159.
DR   PDB; 1RA8; X-ray; 1.80 A; A=1-159.
DR   PDB; 1RA9; X-ray; 1.55 A; A=1-159.
DR   PDB; 1RB2; X-ray; 2.10 A; A/B=1-159.
DR   PDB; 1RB3; X-ray; 2.30 A; A/B=1-159.
DR   PDB; 1RC4; X-ray; 1.90 A; A=1-159.
DR   PDB; 1RD7; X-ray; 2.60 A; A/B=1-159.
DR   PDB; 1RE7; X-ray; 2.60 A; A/B=1-159.
DR   PDB; 1RF7; X-ray; 1.80 A; A=1-159.
DR   PDB; 1RG7; X-ray; 2.00 A; A=1-159.
DR   PDB; 1RH3; X-ray; 2.40 A; A=1-159.
DR   PDB; 1RX1; X-ray; 2.00 A; A=1-159.
DR   PDB; 1RX2; X-ray; 1.80 A; A=1-159.
DR   PDB; 1RX3; X-ray; 2.20 A; A=1-159.
DR   PDB; 1RX4; X-ray; 2.20 A; A=1-159.
DR   PDB; 1RX5; X-ray; 2.30 A; A=1-159.
DR   PDB; 1RX6; X-ray; 2.00 A; A=1-159.
DR   PDB; 1RX7; X-ray; 2.30 A; A=1-159.
DR   PDB; 1RX8; X-ray; 2.80 A; A=1-159.
DR   PDB; 1RX9; X-ray; 1.90 A; A=1-159.
DR   PDB; 1TDR; X-ray; 2.50 A; A/B=1-159.
DR   PDB; 2ANO; X-ray; 2.68 A; A=1-159.
DR   PDB; 2ANQ; X-ray; 2.13 A; A=1-159.
DR   PDB; 2D0K; X-ray; 1.90 A; A/B=2-159.
DR   PDB; 2DRC; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 2INQ; Neutron; 2.20 A; A/B=1-159.
DR   PDB; 3DAU; X-ray; 1.50 A; A=1-159.
DR   PDB; 3DRC; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 3K74; X-ray; 1.95 A; A=1-159.
DR   PDB; 3KFY; X-ray; 2.08 A; A=1-159.
DR   PDB; 3OCH; X-ray; 1.79 A; A/B=1-159.
DR   PDB; 3QL3; X-ray; 1.80 A; A=1-159.
DR   PDB; 3QYL; X-ray; 1.79 A; A=1-159.
DR   PDB; 3QYO; X-ray; 2.09 A; A=1-159.
DR   PDB; 3R33; X-ray; 2.09 A; A=1-159.
DR   PDB; 4DFR; X-ray; 1.70 A; A/B=1-159.
DR   PDB; 4EIG; X-ray; 2.50 A; A=1-159.
DR   PDB; 4EIZ; X-ray; 2.20 A; A/B=1-159.
DR   PDB; 4EJ1; X-ray; 1.75 A; A/B=1-159.
DR   PDB; 4FHB; X-ray; 2.80 A; A=1-159.
DR   PDB; 4GH8; X-ray; 1.85 A; A/B=1-158.
DR   PDB; 4I13; X-ray; 1.60 A; A=1-159.
DR   PDB; 4I1N; X-ray; 1.89 A; A=1-159.
DR   PDB; 4KJJ; X-ray; 1.15 A; A=1-159.
DR   PDB; 4KJK; X-ray; 1.35 A; A=1-159.
DR   PDB; 4KJL; X-ray; 1.38 A; A=1-159.
DR   PDB; 4NX6; X-ray; 1.35 A; A=1-159.
DR   PDB; 4NX7; X-ray; 1.15 A; A=1-159.
DR   PDB; 4PDJ; Other; 1.60 A; A=1-159.
DR   PDB; 4X5F; X-ray; 1.70 A; A/B=1-159.
DR   PDB; 4X5G; X-ray; 1.90 A; A/B=1-159.
DR   PDB; 4X5H; X-ray; 1.90 A; A=1-159.
DR   PDB; 4X5I; X-ray; 1.80 A; A=1-159.
DR   PDB; 4X5J; X-ray; 1.85 A; A=1-159.
DR   PDB; 5CC9; X-ray; 1.20 A; A=1-159.
DR   PDB; 5CCC; X-ray; 1.50 A; A=1-159.
DR   PDB; 5DFR; X-ray; 2.30 A; A=1-159.
DR   PDB; 5E8Q; X-ray; 1.80 A; A/B=1-159.
DR   PDB; 5EAJ; X-ray; 1.70 A; A/B=1-159.
DR   PDB; 6DFR; X-ray; 2.40 A; A=1-159.
DR   PDB; 7DFR; X-ray; 2.50 A; A=1-159.
DR   PDBsum; 1DDR; -.
DR   PDBsum; 1DDS; -.
DR   PDBsum; 1DHI; -.
DR   PDBsum; 1DHJ; -.
DR   PDBsum; 1DRA; -.
DR   PDBsum; 1DRB; -.
DR   PDBsum; 1DRE; -.
DR   PDBsum; 1DRH; -.
DR   PDBsum; 1DYH; -.
DR   PDBsum; 1DYI; -.
DR   PDBsum; 1DYJ; -.
DR   PDBsum; 1JOL; -.
DR   PDBsum; 1JOM; -.
DR   PDBsum; 1RA1; -.
DR   PDBsum; 1RA2; -.
DR   PDBsum; 1RA3; -.
DR   PDBsum; 1RA8; -.
DR   PDBsum; 1RA9; -.
DR   PDBsum; 1RB2; -.
DR   PDBsum; 1RB3; -.
DR   PDBsum; 1RC4; -.
DR   PDBsum; 1RD7; -.
DR   PDBsum; 1RE7; -.
DR   PDBsum; 1RF7; -.
DR   PDBsum; 1RG7; -.
DR   PDBsum; 1RH3; -.
DR   PDBsum; 1RX1; -.
DR   PDBsum; 1RX2; -.
DR   PDBsum; 1RX3; -.
DR   PDBsum; 1RX4; -.
DR   PDBsum; 1RX5; -.
DR   PDBsum; 1RX6; -.
DR   PDBsum; 1RX7; -.
DR   PDBsum; 1RX8; -.
DR   PDBsum; 1RX9; -.
DR   PDBsum; 1TDR; -.
DR   PDBsum; 2ANO; -.
DR   PDBsum; 2ANQ; -.
DR   PDBsum; 2D0K; -.
DR   PDBsum; 2DRC; -.
DR   PDBsum; 2INQ; -.
DR   PDBsum; 3DAU; -.
DR   PDBsum; 3DRC; -.
DR   PDBsum; 3K74; -.
DR   PDBsum; 3KFY; -.
DR   PDBsum; 3OCH; -.
DR   PDBsum; 3QL3; -.
DR   PDBsum; 3QYL; -.
DR   PDBsum; 3QYO; -.
DR   PDBsum; 3R33; -.
DR   PDBsum; 4DFR; -.
DR   PDBsum; 4EIG; -.
DR   PDBsum; 4EIZ; -.
DR   PDBsum; 4EJ1; -.
DR   PDBsum; 4FHB; -.
DR   PDBsum; 4GH8; -.
DR   PDBsum; 4I13; -.
DR   PDBsum; 4I1N; -.
DR   PDBsum; 4KJJ; -.
DR   PDBsum; 4KJK; -.
DR   PDBsum; 4KJL; -.
DR   PDBsum; 4NX6; -.
DR   PDBsum; 4NX7; -.
DR   PDBsum; 4PDJ; -.
DR   PDBsum; 4X5F; -.
DR   PDBsum; 4X5G; -.
DR   PDBsum; 4X5H; -.
DR   PDBsum; 4X5I; -.
DR   PDBsum; 4X5J; -.
DR   PDBsum; 5CC9; -.
DR   PDBsum; 5CCC; -.
DR   PDBsum; 5DFR; -.
DR   PDBsum; 5E8Q; -.
DR   PDBsum; 5EAJ; -.
DR   PDBsum; 6DFR; -.
DR   PDBsum; 7DFR; -.
DR   DisProt; DP00301; -.
DR   ProteinModelPortal; P0ABQ4; -.
DR   SMR; P0ABQ4; -.
DR   BioGrid; 4262199; 282.
DR   DIP; DIP-35824N; -.
DR   IntAct; P0ABQ4; 16.
DR   MINT; MINT-1239602; -.
DR   STRING; 511145.b0048; -.
DR   BindingDB; P0ABQ4; -.
DR   ChEMBL; CHEMBL1809; -.
DR   DrugBank; DB07262; 1-{[N-(1-IMINO-GUANIDINO-METHYL)]SULFANYLMETHYL}-3-TRIFLUOROMETHYL-BENZENE.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB02363; 2'-Monophosphoadenosine-5'-Diphosphate.
DR   DrugBank; DB02718; 5-Formyl-6-Hydrofolic Acid.
DR   DrugBank; DB02015; Dihydrofolic Acid.
DR   DrugBank; DB03904; Urea.
DR   SWISS-2DPAGE; P0ABQ4; -.
DR   EPD; P0ABQ4; -.
DR   PaxDb; P0ABQ4; -.
DR   PRIDE; P0ABQ4; -.
DR   EnsemblBacteria; AAC73159; AAC73159; b0048.
DR   EnsemblBacteria; BAB96616; BAB96616; BAB96616.
DR   GeneID; 944790; -.
DR   KEGG; ecj:JW0047; -.
DR   KEGG; eco:b0048; -.
DR   PATRIC; 32115195; VBIEscCol129921_0049.
DR   EchoBASE; EB0322; -.
DR   EcoGene; EG10326; folA.
DR   eggNOG; ENOG4108YYV; Bacteria.
DR   eggNOG; COG0262; LUCA.
DR   HOGENOM; HOG000040233; -.
DR   InParanoid; P0ABQ4; -.
DR   KO; K00287; -.
DR   OMA; MCITHVE; -.
DR   PhylomeDB; P0ABQ4; -.
DR   BioCyc; EcoCyc:DIHYDROFOLATEREDUCT-MONOMER; -.
DR   BioCyc; MetaCyc:DIHYDROFOLATEREDUCT-MONOMER; -.
DR   BRENDA; 1.5.1.3; 2026.
DR   SABIO-RK; P0ABQ4; -.
DR   UniPathway; UPA00077; UER00158.
DR   EvolutionaryTrace; P0ABQ4; -.
DR   PRO; PR:P0ABQ4; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005829; C:cytosol; IDA:EcoCyc.
DR   GO; GO:0004146; F:dihydrofolate reductase activity; IDA:EcoCyc.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0006545; P:glycine biosynthetic process; IEA:InterPro.
DR   GO; GO:0009165; P:nucleotide biosynthetic process; IEA:InterPro.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   GO; GO:0042493; P:response to drug; IDA:EcoliWiki.
DR   GO; GO:0031427; P:response to methotrexate; IEA:UniProtKB-KW.
DR   GO; GO:0046654; P:tetrahydrofolate biosynthetic process; IEA:UniProtKB-UniPathway.
DR   CDD; cd00209; DHFR; 1.
DR   Gene3D; 3.40.430.10; -; 1.
DR   InterPro; IPR012259; DHFR.
DR   InterPro; IPR024072; DHFR-like_dom.
DR   InterPro; IPR017925; DHFR_CS.
DR   InterPro; IPR001796; DHFR_dom.
DR   Pfam; PF00186; DHFR_1; 1.
DR   PIRSF; PIRSF000194; DHFR; 1.
DR   PRINTS; PR00070; DHFR.
DR   SUPFAM; SSF53597; SSF53597; 1.
DR   PROSITE; PS00075; DHFR_1; 1.
DR   PROSITE; PS51330; DHFR_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic resistance; Complete proteome;
KW   Direct protein sequencing; Methotrexate resistance; NADP;
KW   One-carbon metabolism; Oxidoreductase; Reference proteome;
KW   Trimethoprim resistance.
FT   CHAIN         1    159       Dihydrofolate reductase.
FT                                /FTId=PRO_0000186387.
FT   DOMAIN        1    158       DHFR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00660}.
FT   NP_BIND      13     19       NADP. {ECO:0000269|PubMed:19374017}.
FT   NP_BIND      45     46       NADP. {ECO:0000269|PubMed:19374017}.
FT   NP_BIND      63     64       NADP. {ECO:0000269|PubMed:19374017}.
FT   NP_BIND      95    102       NADP. {ECO:0000269|PubMed:19374017}.
FT   BINDING       5      5       Substrate; via carbonyl oxygen.
FT                                {ECO:0000305|PubMed:9012674}.
FT   BINDING       7      7       NADP; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:19374017}.
FT   BINDING      27     27       Substrate. {ECO:0000305|PubMed:9012674}.
FT   BINDING      52     52       Substrate. {ECO:0000305|PubMed:9012674}.
FT   BINDING      57     57       Substrate. {ECO:0000305|PubMed:9012674}.
FT   BINDING      76     76       NADP; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19374017}.
FT   BINDING     113    113       Substrate. {ECO:0000305|PubMed:9012674}.
FT   VARIANT      28     28       L -> R (in strain: B[RT500] isozyme 2).
FT   VARIANT      30     30       W -> G (in strain: 1810).
FT   VARIANT     154    154       E -> K (in strain: B[MB1428]).
FT   VARIANT     154    154       E -> Q (in strain: 1810).
FT   MUTAGEN      16     16       M->F,S: Increases catalytic rate about 2-
FT                                fold. {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      16     16       M->N: Increases catalytic rate about 2-
FT                                fold. Increases catalytic rate about 7-
FT                                fold; when associated with L-20; Y-42; F-
FT                                92; A-85 and S-152.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      20     20       M->I,V: Increases catalytic rate 2-fold.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      20     20       M->L: Increases catalytic rate 2.5-fold.
FT                                Increases catalytic rate about 7-fold;
FT                                when associated with N-16; Y-42; F-92; A-
FT                                85 and S-152.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      42     42       M->V: Increases catalytic rate almost 2-
FT                                fold. {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      42     42       M->Y: Increases catalytic rate almost 2-
FT                                fold. Increases catalytic rate about 7-
FT                                fold; when associated with N-16; L-20; A-
FT                                85; F-92 and S-152.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      85     85       C->A: Decreases catalytic rate by one
FT                                third. Increases catalytic rate about 7-
FT                                fold; when associated with N-16; L-20; Y-
FT                                42; F-92 and S-152.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      92     92       M->F: No effect. Increases catalytic rate
FT                                about 7-fold; when associated with N-16;
FT                                L-20; Y-42; A-85 and S-152.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN      92     92       M->L: No effect.
FT                                {ECO:0000269|PubMed:16510443}.
FT   MUTAGEN     152    152       C->S: Increases catalytic rate 1.5-fold.
FT                                Increases catalytic rate about 7-fold;
FT                                when associated with N-16; L-20; Y-42; A-
FT                                85 and F-92.
FT                                {ECO:0000269|PubMed:16510443}.
FT   STRAND        2      9       {ECO:0000244|PDB:4KJJ}.
FT   HELIX        10     12       {ECO:0000244|PDB:4KJJ}.
FT   STRAND       13     16       {ECO:0000244|PDB:4KJJ}.
FT   HELIX        17     19       {ECO:0000244|PDB:5CC9}.
FT   HELIX        25     35       {ECO:0000244|PDB:4KJJ}.
FT   STRAND       40     43       {ECO:0000244|PDB:4KJJ}.
FT   HELIX        44     50       {ECO:0000244|PDB:4KJJ}.
FT   STRAND       55     57       {ECO:0000244|PDB:4X5J}.
FT   STRAND       59     62       {ECO:0000244|PDB:4KJJ}.
FT   STRAND       72     77       {ECO:0000244|PDB:4KJJ}.
FT   HELIX        78     85       {ECO:0000244|PDB:4KJJ}.
FT   STRAND       91     93       {ECO:0000244|PDB:4KJJ}.
FT   HELIX        97    103       {ECO:0000244|PDB:4KJJ}.
FT   HELIX       104    106       {ECO:0000244|PDB:4KJJ}.
FT   STRAND      108    115       {ECO:0000244|PDB:4KJJ}.
FT   STRAND      122    124       {ECO:0000244|PDB:4KJJ}.
FT   HELIX       130    132       {ECO:0000244|PDB:4KJJ}.
FT   STRAND      133    141       {ECO:0000244|PDB:4KJJ}.
FT   STRAND      147    149       {ECO:0000244|PDB:4KJJ}.
FT   STRAND      151    158       {ECO:0000244|PDB:4KJJ}.
SQ   SEQUENCE   159 AA;  17999 MW;  6A03CDCD7F5F8562 CRC64;
     MISLIAALAV DRVIGMENAM PWNLPADLAW FKRNTLNKPV IMGRHTWESI GRPLPGRKNI
     ILSSQPGTDD RVTWVKSVDE AIAACGDVPE IMVIGGGRVY EQFLPKAQKL YLTHIDAEVE
     GDTHFPDYEP DDWESVFSEF HDADAQNSHS YCFEILERR
//
